Piras Antonio, Sanfratello Antonella, Boldrini Luca, La Vecchia Maria, Venuti Valeria, Amari Maria Laura, Orlando Marzia, Zichichi Leonardo, Angileri Tommaso, Daidone Antonino
Villa Santa Teresa, Radioterapia Oncologica, Palermo, Italy.
Radioterapia Oncologica, Università degli Studi di, Palermo, Italy.
Dermatol Ther. 2020 Nov;33(6):e13890. doi: 10.1111/dth.13890. Epub 2020 Jul 25.
Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma generally arising in the anogenital region. Surgery is still considered the treatment of choice for patients with EMPD, while Radiotherapy is a common alternative for inoperable cases and it's necessary in case of lack of surgical radicality. In this article, we described our experience and a review of the literature, with a particular focus on radiation-induced toxicity and on the feasibility of re-irradiation. A 70-year-old patient with EPMD underwent adjuvant radiotherapy in 2015. After 28 months for recurrence another radiant treatment was performed. No G3 (CTCAE v4) toxicity were recorded. In the last follow-up visit at 18 months, no signs of relapse were reported. A search strategy of the bibliographic database PubMed was performed. The inclusion criteria for the articles were case report, clinical prospective, or retrospective studies with histological confirmation of EMPD of scrotum and penis; studies with patients undergoing RT; studies in the past 30 years. In most of the 14 reported studies, RT was overall well tolerated. The major observed toxicity was G3 skin toxicity in one study. To our knowledge, there are no other cases of EPMD re-irradiation in literature. Our patient showed an excellent response and tolerated very well the high doses of both the radiation treatments. This suggests that the tolerance of skin to re-irradiation following a long period between the two treatments may be comparable to the normal constraints.
乳房外佩吉特病(EMPD)是一种罕见的皮肤腺癌,通常发生于肛门生殖器区域。手术仍是EMPD患者的首选治疗方法,而放疗是无法手术患者的常见替代方法,且在手术切缘不充分的情况下是必要的。在本文中,我们描述了我们的经验并对文献进行了综述,特别关注了放射诱导的毒性以及再次放疗的可行性。一名70岁的EMPD患者于2015年接受了辅助放疗。28个月后复发,又进行了一次放疗。未记录到3级(CTCAE v4)毒性反应。在最后一次18个月的随访中,未报告复发迹象。我们对文献数据库PubMed进行了检索。纳入标准为:病例报告、临床前瞻性或回顾性研究,且有阴囊和阴茎EMPD的组织学确诊;患者接受放疗的研究;过去30年的研究。在14项已报道的研究中,大多数情况下放疗总体耐受性良好。在一项研究中观察到的主要毒性是3级皮肤毒性。据我们所知,文献中没有其他EMPD再次放疗的病例。我们的患者反应良好,对两次高剂量放疗的耐受性都非常好。这表明两次治疗间隔较长时间后皮肤对再次放疗的耐受性可能与正常限制相当。